Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 15.6% during the second quarter, Holdings Channel.com reports. The firm owned 4,855 shares of the company’s stock after acquiring an additional 655 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Apellis Pharmaceuticals were worth $84,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Assetmark Inc. boosted its position in shares of Apellis Pharmaceuticals by 3,938.7% during the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock worth $27,000 after purchasing an additional 1,221 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after purchasing an additional 855 shares in the last quarter. GF Fund Management CO. LTD. boosted its position in shares of Apellis Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock worth $70,000 after purchasing an additional 573 shares in the last quarter. Legacy Capital Group California Inc. lifted its position in Apellis Pharmaceuticals by 32.8% in the 1st quarter. Legacy Capital Group California Inc. now owns 9,554 shares of the company’s stock valued at $209,000 after acquiring an additional 2,359 shares in the last quarter. Finally, Kaufman Rossin Wealth LLC bought a new position in Apellis Pharmaceuticals in the 1st quarter valued at about $209,000. Institutional investors own 96.29% of the company’s stock.
Apellis Pharmaceuticals Price Performance
Apellis Pharmaceuticals stock opened at $25.15 on Monday. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $35.72. The company’s 50 day moving average price is $25.38 and its two-hundred day moving average price is $21.11. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90. The stock has a market cap of $3.18 billion, a P/E ratio of -13.82 and a beta of 0.69.
Insider Transactions at Apellis Pharmaceuticals
In other news, General Counsel David O. Watson sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $24.34, for a total transaction of $121,700.00. Following the completion of the sale, the general counsel owned 118,730 shares in the company, valued at $2,889,888.20. This trade represents a 4.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Cedric Francois sold 49,963 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $28.39, for a total transaction of $1,418,449.57. Following the sale, the chief executive officer owned 307,946 shares of the company’s stock, valued at approximately $8,742,586.94. The trade was a 13.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 293,454 shares of company stock worth $7,881,527 in the last quarter. Insiders own 6.50% of the company’s stock.
Wall Street Analysts Forecast Growth
APLS has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 8th. Bank of America raised their price target on shares of Apellis Pharmaceuticals from $23.00 to $24.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Citigroup raised their price target on shares of Apellis Pharmaceuticals from $41.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 29th. Cantor Fitzgerald raised their price target on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Finally, Morgan Stanley raised their price target on shares of Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $33.29.
Check Out Our Latest Stock Analysis on APLS
Apellis Pharmaceuticals Profile
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
See Also
- Five stocks we like better than Apellis Pharmaceuticals
- 3 Best Fintech Stocks for a Portfolio Boost
- Microsoft 365 Premium Marks the Next Phase of AI Monetization
- Ride Out The Recession With These Dividend Kings
- Could Target’s Week of Discounts Come Full Circle for Investors?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.